SEARCH

SEARCH BY CITATION

References

  • 1
    Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580585.
  • 2
    Armesto S, Esteve A, Coto-Segura P, Drake M, Galache C, Martinez-Borra J, Santos-Juanes J. Nail Psoriasis in Individuals with Psoriasis Vulgaris: A Study of 661 Patients. Actas Dermosifiliogr 2011; 102: 365372.
  • 3
    Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366372.
  • 4
    Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 127.
  • 5
    De Jong EMGJ, Seegers BAMPA, Gulinck MK, Boezeman JBM, van de Kerkhof PCN. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193: 300303.
  • 6
    Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003; 7: 317321.
  • 7
    Sanchez-Regna M, Umbert P. Diagnosis and management of nail psoriasis. Actas Dermosifiliogr 2008; 99: 3443.
  • 8
    Van Laborde S, Scher RK. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis. A review of the literature. Dermatol Clin 2000; 18: 3746.
  • 9
    Gregoriou S, Kalogeromitros D, Kosionis N, Gkouvi A, Rigopoulos D. Treatment options for nail psoriasis. Expert Rev Dermatol 2008; 3: 339344.
  • 10
    Gladman DD, Anhorn KB, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13: 58692.
  • 11
    Farber EM, Nall L. Nail psoriasis. Cutis 1992; 50: 174178.
  • 12
    Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 127.
  • 13
    Edwards F, de Berker D. Nail psoriasis: clinical presentations and best practice recommendations. Drugs 2009; 69: 235161.
  • 14
    Shemer A, Trau H, Davidovici B, Grunwald MH, Amichai B. Onychomycosis in psoriatic patients – rationalization of systemic treatment. Mycoses 2009; 53: 340343.
  • 15
    Kovich OI, Soldano AC. Clinical pathologic correlations for diagnosis and treatment of nail disorders. Dermatol Ther 2007; 20: 116.
  • 16
    Natarajan V, Nath AK, Thappa DM, Singh R, Verma SK. Coexistence of onychomycosis in psoriatic nails: a descriptive study. Indian J Dermatol Venereol Leprol 2010; 76: 723.
  • 17
    Wilsmann-Theis D, Hagemann T, Dederer H, Wenzel J, Bieber T, Novak N. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol. 2004; 150: 11947.
  • 18
    Gudjonsson JE, Karason A, Antonsdottir A, Runarsdottir EH, Hauksson VB, Upmanyu R, Gulcher J, Stefansson K, Valdimarsson H. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. British Journal of Dermatology 2003; 148: 2335.
  • 19
    Reich K, Hüffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, Traupe H, Mössner R, Reis A, Burkhardt H. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis & Rheumatism 2007; 56: 205664.
  • 20
    Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. American Journal of Human Genetics 2007; 80: 27390.
  • 21
    Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD, Lanchbury J, Barker JN, Trembath RC, Nestle FO. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 2016.
  • 22
    Ash ZR, Tinazzi I, Gallego CC, Kwok C, Wilson C, Goodfield M, Gisondi P, Tan AL, Marzo-Ortega H, Emery P, Wakefield RJ, McGonagle DG, Aydin SZ. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesiopathy than those with normal nails. Ann Rheum Dis 2012; 71: 55361.
  • 23
    McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage– implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218: 97102.
  • 24
    McGonagle D, Tan AL, Benjamin M. The biomechanical link between skin and joint disease in psoriasis and psoriatic arthritis: what every dermatologist needs to know. Ann Rheum Dis 2008; 67: 14.
  • 25
    Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, McGonagle D. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis – a high-resolution MRI and histological study. Rheumatology 2007; 46: 253256.
  • 26
    McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009; 23(Suppl. 1): 913.
  • 27
    Tan Al, Grainger AJ, Tanner SF, Emery P, McGonagle D. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same Arthritis Rheum 2006; 54: 132833.
  • 28
    Augustin M Ogilvie A. Methods of outcomes measurement in nail psoriasis. Dermatology 2010; 221 Suppl 1: 238.
  • 29
    Rich P, Sher RK. Nail Psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206212.
  • 30
    Kacar E, Ergin S, Erdogan BS. The comparison of Nail Psoriasis Severity Index with a less time-consuming qualitative system. J Eur Acad Dermatol Venereol 2008; 22:219222.
  • 31
    Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, Wu CW, Kavanaugh A. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123129.
  • 32
    Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and Validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol 2010; 24: 227.
  • 33
    Augustin M, Blome C, Michaelis-Wittern K, Radtke M, Reich K. For the NAPPA task force group: Conception, development and validation of NAPPA, a novel questionnaire for the assessment of patient-reported outcomes in nail psoriasis. Submitted 2013.
  • 34
    Baran R. The Burden of Nail Psoriasis: An Introduction. Dermatology 2010; 221: 15.
  • 35
    Radtke MA, Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Related Outcomes Measures 2011; 2: 16.
  • 36
    De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg 2009; 28: 3943.
  • 37
    Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20: 6067.
  • 38
    De Berker DA, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 138: 9095.
  • 39
    Gerstein W. Psoriasis and lichen planus of nails. Treatment with triamcinolone. Arch Dermatol 1962; 86: 419421.
  • 40
    Abell E, Samman PD. Intradermal triamcinolone treatment of nail dystrophies. Br J Dermatol 1973; 89: 191197.
  • 41
    Bleeker JJ. Intralesional triamcinolone acetonide using the Port-O-Jet and needle injections in localized dermatoses. Br J Dermatol 1974; 91: 97101.
  • 42
    Peachy RD, Pye RJ, Harman RR. The treatment of psoriatic nail dystrophy with intradermal steroid injections. Br J Dermatol 1976; 95: 7578.
  • 43
    Gerstein W. Psoriasis and lichen planus of nails. Arch Dermatol 1962; 86: 41921.
  • 44
    Baran R, Dawber RPR (eds). Diseases of the Nail and Their Management. Oxford , Blackwell Science, 1984.
  • 45
    De Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357362.
  • 46
    Regana MS, Ezquerra GM, Millet PU, Mateos FL. Treatment of nail psoriasis with 8% clobetasol nail lacquer:positive experience in 10 patients. J Eur Acad Dermatol Venereol 2005; 19: 573577.
  • 47
    Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatolog Treat 1999; 10: 101204.
  • 48
    Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propinate cream. Acta Derm Venereol 2001; 82: 140.
  • 49
    Zakeri M, Valikhani M, Mortazavi H, Barzegari M. Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. Dermatol Online J 2005; 11: 5.
  • 50
    Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE, Benelli C. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: 655659.
  • 51
    Tzung TY, Chen CY, Yang CY, Lo PY, Chen YH. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88: 279280.
  • 52
    Kokelj F, Lavaroni G, Piraccini BM, Tosti A. Nail psoriasis treated with calcipotriol (MC903): an open study. J Dermatol Treat 1994; 5: 149150.
  • 53
    De Jong EM, Menke HE, van Praag MC, van de Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-Fluorouracil in a nail penetration-enhancing vehicle:a double-blind study. Dermatology 1999; 199: 313318.
  • 54
    Fredriksson T. Topically applied fluorouracil in the treatment of psoriasis nails. Arch Dermatol 1974; 110: 7356.
  • 55
    Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25: 2313.
  • 56
    Scher RK, Stiller M, Zhu YI. Tazarotene 0,1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355358.
  • 57
    Marx JL, Scher RK. Response of psoriasis nails to oral photochemotherapy. Arch Dermatol 1980; 116: 10234.
  • 58
    Handfield-Jones SE, Boyle J, Harman RRM. Local PUVA treatment for nail psoriasis. Br J Dermatol 1987; 116: 2801.
  • 59
    Vlachou C, Berth-Jones J. Nail poriasis improvement in a patient treated with fumaric acid esters. J Dermatolog Treat 2007; 18: 1757.
  • 60
    Syuto T, Abe M, Ishibuchi H, Ishikawa O. Successful treatment of psoriasis nails with low-dose cyclosporine administration. Eur J Dermatol 2007; 17: 248249.
  • 61
    Feliciani C, Zampetti A, Forleo P, Cerritelli L, Amerio P, Proietto G, Tulli A, Amerio P. Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg 2004; 8: 122125.
  • 62
    Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10: Suppl 2: S195.
  • 63
    Gümüşel M, Özdemir M, Mevlitoğlu I, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25: 10801084.
  • 64
    Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269271.
  • 65
    Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, van Vollenhoven RF, Leirisalo-Repo M, Fitzgerald O, Kron M, Frank M, Kary S, Kupper H. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394399.
  • 66
    Thaci D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, Saurat JH, Khemis A, Sprøgel P, Esslinger HU, Unnebrink K, Kupper H. A phase IIIb, multicenter, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calicpotriol/betamethasone topical treatment in patients with moderate to severe psoriasis:the BELIEVE study. Br J Dermatol 2010; 163: 402411.
  • 67
    Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, Molta CT, Boggs R. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol 2009; 23: 896904.
  • 68
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Galdman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. Golimumab, a New Human Tumor Necrosis Factor alpha Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis. Arthritis & Rheumatism April 2009; 60: 976986.
  • 69
    Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008: 58: 224231.
  • 70
    Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre double-blind trial. Lancet 2005; 366: 13671374.
  • 71
    Rich P. Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23 P40 monoclonal antibody: results from a phase 3 trial (PHOENIX 1). 2008 EADV Abstract FP1007.